CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline
The DOI matches its Crossref record.
Abstract
The aim of this study was to evaluate the CYP2D6 inhibitory effects of four selective rerotonin re-uptake inhibitors (SSRIs). Thirty-one healthy subjects were phenotyped as extensive metabolizers using the dextromethorphan/dextrorphan (DM/DX) urinary ratio as a marker for CYP2D6 activity before and after 8 days of administration of fluoxetine 60 mg (loading dose strategy), fluvoxamine 100 mg, paroxetine 20 mg, or sertraline 100 mg in a parallel-group design. Statistical analysis was performed on log-transformed DM/DX ratios because of variability within and between treatment groups. DM/DX ratios before (DM/DX(BL)) and after (DM/DX(SSRI)) were compared within and between the four SSRI groups. DM/DX(BL) ratios were not significantly different between the four SSRI treatment groups. Comparing within groups, significant differences between DM/DX(BL) and DM/DX(SSRI) were found for the fluoxetine (p < 0.001; ratio values, 0.020 vs. 0.364) and paroxetine (p = 0.0005, ratio values 0.029 vs. 1.085) but not for the fluvoxamine or sertraline groups. Comparing between groups, significant differences in DM/DX(SSRI) ratios were found for fluoxetine versus sertraline (p = 0.0019, DM/DX = 0.364 vs. 0.057), fluoxetine versus fluvoxamine (p < 0.0001, DM/DX = 0.364 vs. 0.019), paroxetine versus sertraline (p = 0.0026, DM/DX = 1.085 vs. 0.057), and paroxetine versus fluvoxamine (p < 0.0001, DM/DX = 1.085 vs. 0.019). No significant differences were noted between the two potent CYP2D6 inhibitors, fluoxetine and paroxetine, or the two weakest inhibitors, fluvoxamine and sertraline. Five subjects in the fluoxetine and four subjects in the paroxetine groups changed to poor metabolizer phenotype (DM/DX > or = 0.3) after treatment. Although CYP2D6 inhibitory effects of fluvoxamine and sertraline did not yield significant differences from baseline, some subjects exhibited DM/DX ratio increases of 150 to 200%. One paroxetine-treated subject did not exhibit any CYP2D6 inhibition. SSRI dose and plasma concentration may be correlated with the extent of CYP2D6 inhibition and should be further investigated.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Kirchheiner, J., Nickchen, K., Bauer, M., Wong, M.-L., Licinio, J., Roots, I., & Brockmöller, J. (2004) · Molecular Psychiatry · doi:10.1038/sj.mp.4001494 · Cited by 724
Clinical Pharmacokinetics of Sertraline
DeVane, C. L., Liston, H. L., & Markowitz, J. S. (2002) · Clinical Pharmacokinetics · doi:10.2165/00003088-200241150-00002 · Cited by 404
de Leon, J., Armstrong, S. C., & Cozza, K. L. (2006) · Psychosomatics · doi:10.1176/appi.psy.47.1.75 · Cited by 300
Pathophysiology of depression and mechanisms of treatment
Brigitta, B. (2002) · Dialogues in Clinical Neuroscience · doi:10.31887/dcns.2002.4.1/bbondy · Cited by 286
Bertelsen, K. M., Venkatakrishnan, K., von Moltke, L. L., Obach, R. S., & Greenblatt, D. J. (2003) · Drug Metabolism and Disposition · doi:10.1124/dmd.31.3.289 · Cited by 276
Metadata
- Authors
- Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L.
- Venue
- Journal of Clinical Psychopharmacology
- Published
- 1999-04
- Volume
- 19
- Issue
- 2
- Pages
- 155-163
- ISSN
- 0271-0749 (ISSN-L)
- OpenAlex
- W2320195367
- Cited by
- 94
- References
- 0
- FWCI
- 8.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline. https://app.cochat.ai/papers/10.1097/00004714-199904000-00011
- The paper
- Alfaro, C. L., Lam, Y. W. F., Simpson, J., & Ereshefsky, L. (1999). CYP2D6 Status of Extensive Metabolizers After Multiple-Dose Fluoxetine, Fluvoxamine, Paroxetine, or Sertraline. Journal of Clinical Psychopharmacology. https://doi.org/10.1097/00004714-199904000-00011
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.